Digital Thermal Monitoring for Endothelial Dysfunction
Trial Summary
What is the purpose of this trial?
This trial measures how well blood vessels work by checking finger temperature changes after stopping and restarting blood flow. It focuses on children and young adults undergoing a major medical procedure. The goal is to see if this method can effectively measure their vascular health.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What data supports the idea that Digital Thermal Monitoring for Endothelial Dysfunction is an effective treatment?
The available research shows that Digital Thermal Monitoring (DTM) is useful for assessing vascular function, which is important for understanding endothelial dysfunction. One study found that DTM correlates with known coronary artery disease, suggesting it can effectively monitor vascular health. However, the research does not directly show DTM as a treatment but rather as a tool for assessment. There is no direct comparison to other treatments for endothelial dysfunction in the provided data.12345
What safety data exists for Digital Thermal Monitoring for Endothelial Dysfunction?
The safety of Digital Thermal Monitoring (DTM) for assessing endothelial dysfunction is supported by studies that demonstrate its noninvasive nature and its correlation with established methods like Doppler flow velocity. The VENDYS® device, used in a study with patients having Continuous Flow-Left Ventricular Assist Devices, showed no association with adverse events, indicating its safety in clinical settings.12367
Is Digital Thermal Monitoring a promising treatment for endothelial dysfunction?
Digital Thermal Monitoring is a promising treatment because it offers a non-invasive way to assess endothelial function, which is important for detecting early signs of heart disease. It uses temperature changes to evaluate how well blood vessels are working, making it easier to identify problems early on.128910
Research Team
Dristhi Ragoonanan, MD
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
This trial is for children and young adults aged 6-26 who are about to undergo or have recently had a hematopoietic cell transplant (HCT). It includes both recipients within a month before/after HCT and healthy donors. Participants must fit the device on their index finger without pain or difficulty, consent to join, and not have skin toxicity or neuropathy affecting device use.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Assessment
Participants undergo a single measurement of vascular health using the Vendys II device
Follow-up
Participants are monitored for any adverse events following the assessment
Treatment Details
Interventions
- Vendys II Device
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor